VX-548 for Sciatica

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Vertex Pharmaceuticals Incorporated

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new medication called VX-548 to see if it can help people with PLSR, a condition that might not respond well to typical treatments. The study aims to find out if VX-548 can reduce symptoms or improve health safely.

Eligibility Criteria

This trial is for individuals who have been experiencing sciatica or radiculopathy pain for more than 3 months. Participants must have a consistent moderate level of pain and meet specific body weight (over 45 kg) and BMI (40 kg/m^2 or less) requirements.

Inclusion Criteria

My weight is at least 45 kg.

Treatment Details

The study aims to test the effectiveness and safety of a medication called VX-548 in treating painful lumbosacral radiculopathy. Some participants will receive VX-548, while others will be given a placebo to compare results.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: VX-548Experimental Treatment1 Intervention

Participants will receive VX-548 up to 12 weeks.

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive placebo matched to VX-548 up to 12 weeks.